Stock Market & Financial Investment News

News Breaks December 14, 2012 15:50 EDT DUSA Dusa Pharmaceuticals says Phase 2 clinical trial statistically significant Dusa Pharmaceuticals reported preliminary results of a Phase 2 clinical trial investigating the use of the Levulan Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment with Levulan Kerastick — after incubating for one, two or three hours — resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count when compared to treatment with vehicle 12 weeks post treatment, the company said. News For DUSA From The Last 14 Days Check below for free stories on DUSA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for DUSA Sign up for a free trial to see the rest of the stories you've been missing.